Abstract
The promotion of cellular survival, dedifferentiation, and uncontrolled proliferation via the suppression of apoptotic effectors is a fundamental characteristic of tumor cells. As substrates that are negatively regulated by oncogenic signaling cascades driven by AKT, SGK (serum- and glucocorticoid-inducible kinase), IkB kinase (IKK), ERK, and cyclin-dependent kinases (CDK), forkhead box-class O (FOXO) transcription factors have emerged as bona fide tumor suppressors. These transcription factors indeed regulate a variety of cellular responses and themselves are regulated by reversible phosphorylation, acetylation, ubiquitination and miRNAs. This review will discuss our current understanding of mechanisms for FOXO regulation and the potential implications for therapeutically restoring FOXO transcriptional activity.
Keywords: Apoptosis, FOXO, TRAIL, BIM, PP2A, proteasome, 14-3-3, micro RNA, PI3K, AKT, MIRNA, VELCADE, PS-341
Current Drug Targets
Title: Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Volume: 12 Issue: 9
Author(s): Amrik Singh, Jessica Plati and Roya Khosravi-Far
Affiliation:
Keywords: Apoptosis, FOXO, TRAIL, BIM, PP2A, proteasome, 14-3-3, micro RNA, PI3K, AKT, MIRNA, VELCADE, PS-341
Abstract: The promotion of cellular survival, dedifferentiation, and uncontrolled proliferation via the suppression of apoptotic effectors is a fundamental characteristic of tumor cells. As substrates that are negatively regulated by oncogenic signaling cascades driven by AKT, SGK (serum- and glucocorticoid-inducible kinase), IkB kinase (IKK), ERK, and cyclin-dependent kinases (CDK), forkhead box-class O (FOXO) transcription factors have emerged as bona fide tumor suppressors. These transcription factors indeed regulate a variety of cellular responses and themselves are regulated by reversible phosphorylation, acetylation, ubiquitination and miRNAs. This review will discuss our current understanding of mechanisms for FOXO regulation and the potential implications for therapeutically restoring FOXO transcriptional activity.
Export Options
About this article
Cite this article as:
Singh Amrik, Plati Jessica and Khosravi-Far Roya, Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer, Current Drug Targets 2011; 12 (9) . https://dx.doi.org/10.2174/138945011796150271
DOI https://dx.doi.org/10.2174/138945011796150271 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets HE4 is a Beneficial Biomarker in Endometrial Adenocarcinoma
Current Women`s Health Reviews Microbicides for Prevention of Transmission of Sexually Transmitted Diseases
Current Pharmaceutical Design PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Decision Support System for Lymphoma Classification
Current Medical Imaging The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Decreased Expression and Altered Methylation of Syncytin-1 Gene in Human Placentas Associated with Preeclampsia
Current Pharmaceutical Design Towards Prevention of Ovarian Cancer
Current Cancer Drug Targets Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Cell Responses to Oxidative Stressors
Current Pharmaceutical Design